查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138269

2022-2029 年全球皮膚癌市場

Global Skin Cancer Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球皮膚癌市場的增長是由皮膚癌發病率增加、全球變暖加劇導致臭氧消耗以及治療意識的提高推動的，尤其是在新興國家。

皮膚癌確診人數不斷增加，有望成為市場增長的驅動力。

1994 年至 2020 年間，美國非黑色素瘤皮膚癌的診斷和治療增加了 77%。大約 90% 的非黑色素瘤皮膚癌與陽光暴露於紫外線 (UV) 輻射有關。根據美國皮膚病學會的數據，美國每天約有 9,500 人被診斷出患有皮膚癌。估計到 2021 年美國將診斷出 196,060 例新的黑色素瘤，其中包括 101,280 例原位黑色素瘤和 106,110 例侵襲性黑色素瘤。預計到 2021 年，侵襲性黑色素瘤將成為男性（62,260 例）和女性（43,850 例）中第五大最常診斷的癌症。非西班牙裔白人的皮膚癌發病率大約是非西班牙裔黑人和亞洲/太平洋島民的 30 倍。皮膚白皙的人的皮膚癌通常在難以治療的後期被診斷出來。

當癌症擴散到附近的淋巴結時，25% 的非裔美國人黑色素瘤患者被診斷出來。另一方面，當癌症擴散到遠處的淋巴結或其他器官時，16% 的人被診斷出來。據說皮膚癌更容易發生在沒有暴露在陽光下的部位，例如手掌、腳底、腹股溝和嘴巴周圍。黑色素瘤也可以在指甲下形成。 50 歲之前女性的皮膚癌發病率高於男性，50 歲之後的男性發病率更高，這與娛樂和工作相關的紫外線照射的差異有關。似乎研究表明，在 15 至 39 歲之間被診斷出患有黑色素瘤的男性比同年齡段被診斷出患有黑色素瘤的女性死亡的可能性高 55%。因此，在預測期內，增加皮膚癌診斷將推動市場的增長。

皮膚癌診斷的高成本預計將阻礙市場增長。

平均 150,000 美元的癌症治療費用是治療其他常見疾病費用的四倍多。根據疾病控制和預防中心 (CDC) 的數據，治療所有類型的皮膚癌估計每年至少花費 80 億美元。該機構估計，到 2030 年，治療新的黑色素瘤患者的費用將達到 16 億美元。因此，這些因素將阻礙預測期內的市場增長。

行業分析

皮膚癌市場根據波特五力、未滿足的需求、流行病學和供應鏈分析等各種行業因素對市場進行深入分析。

細分分析

在預測期間（2022-2029 年），非黑色素瘤部分預計將以最快的複合年增長率增長。

非黑色素瘤皮膚癌在早期通常被視為簡單的病變，但如果治療不當，會迅速擴散到身體的其他部位。目前，全世界每年約有 200 萬例非黑色素瘤皮膚癌病例和約 132,000 例黑色素瘤皮膚癌病例發生。此外，根據美國臨床腫瘤學會 (ASCO) 的估計，到 2022 年，美國每年將有 330 萬人中的 540 萬人被診斷出患有基底細胞癌和鱗狀細胞癌。有些人被診斷出患有不止一種皮膚癌。幾年來，除黑色素瘤以外的皮膚癌數量一直在增加。這可能是由於早期發現疾病、增加陽光照射和延長壽命。基底細胞癌比鱗狀細胞癌更常見。除黑色素瘤外，大約 80% 的皮膚癌是基底細胞癌。因此，它是美國最常見的惡性腫瘤，具有相當大的相關發病率和成本以及相對較小但顯著的死亡率。非黑色素瘤皮膚癌的治療通常是成功的，因為與其他類型的癌症不同，癌症擴散到身體其他部位的風險顯著降低。治療黑色素瘤以外的皮膚癌在大約 90% 的病例中是成功的。因此，預計非黑色素瘤皮膚癌發病率和治療後成功率的增加將推動預測期內的市場增長。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和皮膚癌市場產生了負面影響。根據發表在 Cancer Connect 2020 上的一篇文章，Dana-Farber Cancer Institute 的醫生髮現，在 COVID-19 流行期間，包括皮膚癌在內的六種最常見癌症的診斷率下降了 46%。此外，美國疾病控制和預防中心 (CDC) 和許多醫療保健專業人員正在推遲健康預防服務，例如癌症篩查和擇期手術，除非風險大於收益，並敦促人們治療 COVID-19 患者. 他建議保護醫院基礎設施。因此，COVID-19 大流行正在影響皮膚癌市場。

全球皮膚癌市場報告提供對大約 45 多個市場數據表、40 多個圖表和 180 頁的訪問。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按適應症類型劃分的市場細分
  • 按處理方法劃分的市場細分
  • 按診斷劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 提高對皮膚癌治療的認識
      • 皮膚癌診斷人數增加
    • 抑制因素
      • 皮膚癌診斷的高昂費用阻礙了市場增長。
    • 商機
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章適應症

  • 黑色素瘤
  • 非黑色素瘤
    • 基底細胞癌
    • 鱗狀細胞癌
    • 默克爾細胞癌

第 8 章治療

  • 化療
  • 光動力療法
  • 免疫療法
  • 靶向治療
  • 放射治療
  • 其他治療

第 9 章診斷

  • 皮膚鏡檢查
  • 皮膚活檢
  • 淋巴結活檢
  • 圖像檢查
  • 驗血
  • 其他

第 10 章最終用戶

  • 醫院
  • 癌症研究所
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司

第 13 章公司簡介

  • Amgen, Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories.
  • Sanofi SA
  • Novartis AG
  • Qiagen NV
  • Pfizer Inc.（*LIST NOT EXHAUSTIVE）

第 14 章數據M

簡介目錄
Product Code: DMPH319

Market Overview

Skin Cancer Market is expected to grow at a CAGR 8% during the forecasting period (2022-2029). Skin cancer is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of skin cancer is caused majorly due to solar and artificial ultraviolet radiation (UV). Ultraviolet radiation is a primary carcinogen that results in UV-induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies.

The Skin Cancer Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Skin Cancer Market segmentation by treatment type, and end user. It also provides Skin Cancer Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Skin Cancer Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global skin cancer market growth is driven by the growing incidents of skin cancer, rise in global warming leading to depletion of ozone layer and increasing awareness about the treatment especially in the emerging nations.

The growing diagnosis of skin cancer is expected to drive market growth.

The diagnosis and treatment of nonmelanoma skin cancers in the U.S. increased by 77 percent between 1994 and 2020. About 90 percent of nonmelanoma skin cancers are associated with sun exposure to ultraviolet (UV) radiation. The American Academy of Dermatology Association, approximately 9,500 people in the U.S. are diagnosed with skin cancer daily. It is estimated that 196,060 new cases of melanoma, 101,280 noninvasive (in situ), and 106,110 invasives will be diagnosed in the U.S. in 2021. Invasive melanoma is projected to be the fifth most commonly diagnosed cancer for men (62,260 cases) and women (43,850 cases) in 2021. The incidence of skin cancer among non-Hispanic white individuals is almost 30 times higher than that among non-Hispanic Black or Asian/Pacific Islander individuals. Skin cancer in patients with skin color is often diagnosed in its later stages when it's more difficult to treat.

Twenty-five percent of melanoma cases in African American patients are diagnosed when cancer has spread to nearby lymph nodes. In contrast, 16% are diagnosed when cancer has spread to distant lymph nodes and other organs. People with skin color are prone to skin cancer in areas that aren't commonly exposed to the sun, like the palms of the hands, the soles of the feet, the groin and the mouth. They also may develop melanoma under their nails. Skin cancer rates are higher in women than in men before age 50 but are higher in men after age 50, which may be related to differences in recreation and work-related UV exposure. Research indicates that males diagnosed with melanoma between the ages of 15 and 39 are 55% more likely to die than females diagnosed with melanoma in the same age group. Thus, the growing skin cancer diagnosis will drive the market's growth in the forecast period.

The high cost of skin cancer diagnosis is expected to hamper the market growth.

At an average of $150,000, cancer treatment costs are more than four times higher than treatment for other common health conditions. As per the Centers for Disease Control and Prevention (CDC), it is estimated that treatment for all kinds of skin cancer costs at least $8 billion per year. The agency projects that the annual cost of treating new patients with melanoma will be $1.6 billion by 2030. Thus these factors will hamper the market's growth in the forecast period.

Industry Analysis

The skin cancer market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, epidemiology, supply chain analysis etc.

Segmentation Analysis

The Non-melanoma segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages, but if not treated properly, it can quickly spread to other body parts. Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally yearly. Moreover, according to the American Society of Clinical Oncology (ASCO), in 2022, it is estimated that 5.4 million cases of basal cell carcinoma and squamous cell carcinoma will be diagnosed annually in the United States among 3.3 million people. Some people are diagnosed with more than 1 skin cancer. The number of non-melanoma skin cancers has been growing for several years. This is likely due to earlier detection of the disease, increased sun exposure, and longer life spans. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancers are basal cell carcinoma. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost and relatively small but significant mortality. Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk of cancer spreading to other parts of the body. Treatment for non-melanoma skin cancer is successful in approximately 90% of cases. Hence, the increasing rates of non-melanoma skin cancer and its success rates after treatment will drive the market's growth in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global skin cancer market.

In 2021, the North American region accounted for the largest market share. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, according to the latest SEER data, melanoma is the fifth most common cancer diagnosis in the US (excluding non-melanoma skin cancers), with 106,000 estimated new cases in 2021, representing 5.6% of all cancer diagnoses. Thus, the increasing incidences of skin cancer in the region are a major factor driving the market growth.

Additionally, the recent advancements in skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus driving the growth of the skin cancer market during the forecast period. For instance, Nanotechnology-based therapy is gaining popularity and becoming an essential topic to debate. Skin cancer nanotherapy is approached in a variety of ways and tactics. Nanoparticles targeting carcinoma cells, functionalized nanoparticles for specific targeting to cancer cells, receptor-mediated active targeting as nanoshells, nanostructured lipid carriers, liposome, ethosome, bilosome, polymeric nanoparticle, nanosphere, dendrimers, carbon nanotubes, quantum dots, solid lipid nanoparticles, and fullerenes that are highly efficient in the specific killing of cancer cells are all examples of strategic approaches.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems and the skin cancer market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types, including skin cancer. Moreover, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweigh the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the skin cancer market.

Competitive Landscape

Major key players in the skin cancer market are Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Abbott Laboratories., Sanofi SA, Novartis AG, Qiagen NV and Pfizer Inc. among others.

Amgen:

Overview:

Amgen is one of the world's leading biotechnology companies. It is engaged in pharmaceutical product research, development, and manufacturing. Amgen is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. The company offers a wide range of products for treating the central nervous system, neurosciences, ophthalmology, cancer, medical aesthetics, plastic surgery, dermatology, liver disease, inflammation, metabolic syndromes, and fibrosis. Amgen has 40 manufacturing facilities and 27 R&D, and Amgen, Inc is a biotechnology company that engages in the discovery, development, manufacture and marketing of human therapeutics and marketing facilities across the world.

­Product Portfolio:

IMLYGIC: IMLYGIC (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands.

The global skin cancer market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Indication Type
  • 3.2. Market snippet By Treatment
  • 3.3. Market snippet By Diagnosis
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about the treatment of skin cancer
      • 4.1.1.2. The growing diagnosis of skin cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of skin cancer diagnosis will hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
    • 7.1.2. Market Attractiveness Index, By Indication Type Segment
  • 7.2. Melanoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-melanoma
    • 7.3.1. Basal cell carcinoma
    • 7.3.2. Squamous cell carcinoma.
    • 7.3.3. Merkel cell cancer

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Photodynamic Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Radiation Therapy
  • 8.7. Other Treatments

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 9.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 9.2. Dermatoscopy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Skin Biopsy
  • 9.4. Lymph Node Biopsy
  • 9.5. Imaging Tests
  • 9.6. Blood Tests
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Cancer Research Institutes
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. Key Companies to Watch

13. Company Profiles

  • 13.1. Amgen, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. F. Hoffmann-La Roche Ltd
  • 13.4. Merck & Co., Inc.
  • 13.5. Sun Pharmaceutical Industries Ltd.
  • 13.6. Abbott Laboratories.
  • 13.7. Sanofi SA
  • 13.8. Novartis AG
  • 13.9. Qiagen NV
  • 13.10. Pfizer Inc.(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us